Does Cyp3a Inducers Interact with Ruxolitinib?
Cyp3a Inducers and Ruxolitinib have a moderate drug interaction according to U.S. FDA drug labeling data. Inducers of CYP3A4 may decrease ruxolitinib systemic concentrations, potentially reducing efficacy. The mechanism involves induction of cyp3a4-mediated metabolism of ruxolitinib. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Ruxolitinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inducers and Ruxolitinib occurs because induction of cyp3a4-mediated metabolism of ruxolitinib. Clinically, this means inducers of cyp3a4 may decrease ruxolitinib systemic concentrations, potentially reducing efficacy. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Ruxolitinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider